文献速递血管炎

度普利尤单抗治疗嗜酸性肉芽肿性多血管炎复发或难治性鼻窦和/或哮喘表现:一项欧洲回顾性研究

Dupilumab for relapsing or refractory sinonasal and/or asthma manifestations in eosinophilic granulomatosis with polyangiitis: a European retrospective study.
PubMed 文献 · Ann Rheum Dis · 2023-09-21

这项欧洲多中心观察性研究纳入51例接受度普利尤单抗治疗的嗜酸性肉芽肿性多血管炎(EGPA)患者,主要适应证为致残性耳鼻喉症状(92%)。中位随访13.1个月后,41%达完全缓解、24%达部分缓解,但31%出现EGPA复发,其中88%复发前有血嗜酸性粒细胞增多;35%报告不良事件,67%出现嗜酸性粒细胞增多。作者认为度普利尤单抗可能对EGPA相关耳鼻喉表现有效,但需谨慎。

要点

  • 51例EGPA患者中92%因致残性耳鼻喉症状使用度普利尤单抗,41%完全缓解、24%部分缓解。
  • 31%患者在度普利尤单抗治疗期间出现EGPA复发,其中88%复发前有血嗜酸性粒细胞增多。
  • 67%出现嗜酸性粒细胞增多,峰值中位2195/mm3,出现在中位13周;35%报告不良事件,含2例严重不良事件。

核心结论

  • 作者认为度普利尤单抗可能对治疗EGPA相关耳鼻喉表现有效,但三分之一的患者出现EGPA复发且88%复发前有嗜酸性粒细胞增多,提示需要谨慎。

研究设计与样本

  • 欧洲多中心观察性研究,纳入51例接受度普利尤单抗治疗的EGPA患者。
  • 完全缓解定义为BVAS=0且泼尼松剂量≤4 mg/天,部分缓解定义为BVAS=0且泼尼松剂量>4 mg/天。
  • 嗜酸性粒细胞增多定义为嗜酸性粒细胞计数>500/mm3。

主要发现

  • 度普利尤单抗的主要适应证为致残性耳鼻喉症状,占92%。
  • 中位随访13.1个月后,18例(35%)报告不良事件,包括2例严重不良事件。
  • 34例(67%)报告嗜酸性粒细胞增多,峰值中位2195/mm3(IQR 1268-4501),出现在中位13周(IQR 4-36),并与41%的复发相关。
  • 21例(41%)达完全缓解,12例(24%)达部分缓解;16例(31%)在度普利尤单抗治疗期间出现EGPA复发,其中14/16(88%)伴有血嗜酸性粒细胞增多。
  • 复发者开始度普利尤单抗时的中位嗜酸性粒细胞计数显著低于非复发者,停用抗IL-5/IL-5R与换用度普利尤单抗之间的中位时间也显著更短。

关键数值与推荐

  • 完全缓解:BVAS=0且泼尼松剂量≤4 mg/天;部分缓解:BVAS=0且泼尼松剂量>4 mg/天。
  • 嗜酸性粒细胞增多:嗜酸性粒细胞计数>500/mm3。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Eosinophilic granulomatosis with polyangiitis (EGPA) is often associated with glucocorticoid-dependent asthma and/or ear, nose and throat (ENT) manifestations. When immunosuppressants and/or mepolizumab are ineffective, dupilumab could be an option. We describe the safety and efficacy of off-label use of dupilumab in relapsing and/or refractory EGPA. PATIENTS AND METHODS: We conducted an observational multicentre study of EGPA patients treated with dupilumab. Complete response was defined by Birmingham Vasculitis Activity Score (BVAS)=0 and prednisone dose ≤4 mg/day, and partial response by BVAS=0 and prednisone dose >4 mg/day. Eosinophilia was defined as an eosinophil count >500/mm3. RESULTS: Fifty-one patients were included. The primary indication for dupilumab was disabling ENT symptoms in 92%. After a median follow-up of 13.1 months, 18 patients (35%) reported adverse events (AEs), including two serious AEs. Eosinophilia was reported in 34 patients (67%), with a peak of 2195/mm3 (IQR 1268-4501) occurring at 13 weeks (IQR 4-36) and was associated with relapse in 41%. Twenty-one patients (41%) achieved a complete response and 12 (24%) a partial response. Sixteen (31%) patients experienced an EGPA relapse while on dupilumab, which was associated with blood eosinophilia in 14/16 (88%) patients. The median eosinophil count at the start of dupilumab was significantly lower in relapsers than in non-relapsers, as was the median time between stopping anti-IL-5/IL-5R and switching to dupilumab. CONCLUSION: These results suggest that dupilumab may be effective in treating patients with EGPA-related ENT manifestations. However, EGPA flares occurred in one-third of patients and were preceded by eosinophilia in 88%, suggesting that caution is required.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Molina B, Padoan R, Urban ML, et al. Dupilumab for relapsing or refractory sinonasal and/or asthma manifestations in eosinophilic granulomatosis with polyangiitis: a European retrospective study. Ann Rheum Dis. 2023. PMID: 37734881. doi:10.1136/ard-2023-224756

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。